JOT is developing JOTROL™ for Alzheimer's Disease in parallel with Friedreich's Ataxia to utilize the possible fast approval and income stream of a rare disease to fund AD development. Additional rare diseases might be developed later.
Upcoming results from Phase I Pharmacokinetics Study will be cross-referenced, works as an FDA "master file", for all future JOTROL™ indications enabling direct to Phase II trials.
Upcoming results from Phase I Pharmacokinetics Study will be cross-referenced, works as an FDA "master file", for all future JOTROL™ indications enabling direct to Phase II trials.